In early July 2021, the SA Health Products Regulatory Authority (SAHPRA) announced that it had authorised emergency use of CoronaVac, and in June 2022.
Coronavac received full registration from SAHPRA. CoronaVac is an inactivated Covid-19 vaccine manufactured by Sinovac Biotech (China) the Numolux Group is their South African in-country partner.
CoronaVac is an inactivated vaccine against COVID-19, based on the technology of vaccines which have been successfully used in immunisation programmes, in South Africa and across the globe, for decades. These type of vaccines are often a preferred product class for special populations and public members. CoronaVac has been administered to over 2.8 billion people worldwide. Receiving full registration for this vaccine in South Africa is no small feat, and is the culmination of commitment and hard work by our team, Sinovac and all involved. It is an achievement that we are immensely proud of.
Undoubtedly, one of our greatest triumphs came about as part of our paediatric clinical trials. The Numolux Group and Sinovac, successfully vaccinated the first 6 month old baby in the world with the inactivated CoronaVac Covid-19 vaccine, at one of our South African clinical trial sites. We are pleased to report that nearly one year after vaccination – no serious adverse effects (SAE) have been observed in the baby.
We firmly believe that every person has the right to choose which vaccine they are administered, and we are hopeful that CoronaVac will soon be made available to those in South Africans who wish to use it.